PAVmed
PAVM
62 hedge funds and large institutions have $4.62M invested in PAVmed in 2022 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 12 increasing their positions, 20 reducing their positions, and 14 closing their positions.
942% more call options, than puts
Call options by funds: $125K | Put options by funds: $12K
0.01% less ownership
Funds ownership: 0.03% → 0.02% (-0.01%)
11% less funds holding
Funds holding: 70 → 62 (-8)
40% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 20
57% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 14
58% less capital invested
Capital invested by funds: $10.9M → $4.62M (-$6.32M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCS
Levin Capital Strategies
New York
|
+$109K |
| 2 |
BAM
Belpointe Asset Management
Reno,
Nevada
|
+$79.7K |
| 3 |
Wells Fargo
San Francisco,
California
|
+$48.3K |
| 4 |
Bank of New York Mellon
New York
|
+$26.1K |
| 5 |
VF
Virtu Financial
New York
|
+$23K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Ayrton Capital
Westport,
Connecticut
|
-$1.38M |
| 2 |
KPWS
Kestra Private Wealth Services
Austin,
Texas
|
-$860K |
| 3 |
E
Ergoteles
New York
|
-$183K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$91.4K |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$49K |
PAVM Hedge Fund Activity: Q4 2022 in Review
62 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in PAVmed (PAVM) for Q4 2022, worth a combined $4.62M — down 58% from $10.9M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of PAVM and 6 opened new positions — a net loss of 8 holders — while 20 trimmed existing stakes and 12 added.
The largest buyer was Levin Capital Strategies, adding an estimated $109K. The largest seller was Ayrton Capital, exiting entirely with an estimated $1.38M sold.
- 62 institutional investors held PAVmed (PAVM) as of Q4 2022, down from 70 in Q3 2022.
- Funds reported $4.62M of PAVmed stock for Q4 2022, down 58% quarter-over-quarter.
- 6 funds opened new PAVmed positions in Q4 2022 and 14 closed out, a net change of -8 holders.
- The largest PAVmed buyer in Q4 2022 was Levin Capital Strategies, an estimated $109K added.
- The largest PAVmed seller in Q4 2022 was Ayrton Capital, an estimated $1.38M sold.
Based on aggregated 13F filings for Q4 2022.